Abstract

Classic Hodgkin lymphoma (cHL) stands out as success story in the field of medical oncology, with multiagent chemotherapy with or without radiation leading to durable remission for most patients. Large-scale clinical trials during the past 40 years have sought to minimize toxicities while maintaining strong efficacy, including efforts to reduce the size of radiation fields, minimize alkylator chemotherapy, reduce the number of chemotherapy cycles, and omit radiation in select populations. The last decade has also ushered in novel therapies, including brentuximab vedotin (BV), that have improved clinical outcomes for patients with cHL resistant to standard cytotoxic therapies. More recently, a large randomized trial compared BV plus chemotherapy with chemotherapy alone for first-line treatment of advanced stage cHL. With ∼24 months of available follow-up, the BV containing regimen was found to be associated with a reduction in the risk of progression, death, or incomplete response to first-line treatment (modified progression-free survival). Whether this early signal of improved efficacy is worth the additional acute toxicities and added drug-related expenses associated with incorporating BV into first-line treatment remains controversial. This chapter provides historical background; reviews the cost-effectiveness of available cHL therapies; and summarizes potential ways to balance innovation, affordability, and patient access to novel therapeutics.

References

References
1.
DeVita
VT
Jr
,
Chu
E
.
A history of cancer chemotherapy
.
Cancer Res
.
2008
;
68
(
21
):
8643
-
8653
.
2.
Canellos
GP
,
Anderson
JR
,
Propert
KJ
, et al
.
Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD
.
N Engl J Med
.
1992
;
327
(
21
):
1478
-
1484
.
3.
Diehl
V
,
Franklin
J
,
Pfreundschuh
M
, et al
;
German Hodgkin’s Lymphoma Study Group
.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease [published erratum appears in N Engl J Med. 2005;353(7):744]
.
N Engl J Med
.
2003
;
348
(
24
):
2386
-
2395
.
4.
Schaapveld
M
,
Aleman
BMP
,
van Eggermond
AM
, et al
.
Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma
.
N Engl J Med
.
2015
;
373
(
26
):
2499
-
2511
.
5.
Engert
A
,
Plütschow
A
,
Eich
HT
, et al
.
Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma
.
N Engl J Med
.
2010
;
363
(
7
):
640
-
652
.
6.
Johnson
P
,
Federico
M
,
Kirkwood
A
, et al
.
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
.
N Engl J Med
.
2016
;
374
(
25
):
2419
-
2429
.
7.
Radford
J
,
Illidge
T
,
Counsell
N
, et al
.
Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma
.
N Engl J Med
.
2015
;
372
(
17
):
1598
-
1607
.
8.
André
MPE
,
Girinsky
T
,
Federico
M
, et al
.
Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial
.
J Clin Oncol
.
2017
;
35
(
16
):
1786
-
1794
.
9.
Fuchs
M
,
Goergen
H
,
Kobe
C
, et al
.
PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study Group [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
925
.
10.
Viviani
S
,
Zinzani
PL
,
Rambaldi
A
, et al
;
Intergruppo Italiano Linfomi
.
ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned
.
N Engl J Med
.
2011
;
365
(
3
):
203
-
212
.
11.
Hoppe
RT
,
Advani
RH
,
Ai
WZ
, et al
.
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
.
J Natl Compr Canc Netw
.
2017
;
15
(
5
):
608
-
638
.
12.
Eichenauer
DA
,
Aleman
BMP
,
André
M
, et al
;
ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines
.
Ann Oncol
.
2018
;
29
(
suppl 4
):
iv19
-
iv29
.
13.
Sureda
A
,
Constans
M
,
Iriondo
A
, et al
;
Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group
.
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse
.
Ann Oncol
.
2005
;
16
(
4
):
625
-
633
.
14.
Martínez
C
,
Canals
C
,
Sarina
B
, et al
;
Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
.
Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation
.
Ann Oncol
.
2013
;
24
(
9
):
2430
-
2434
.
15.
Younes
A
,
Gopal
AK
,
Smith
SE
, et al
.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma
.
J Clin Oncol
.
2012
;
30
(
18
):
2183
-
2189
.
16.
Gopal
AK
,
Chen
R
,
Smith
SE
, et al
.
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
.
Blood
.
2015
;
125
(
8
):
1236
-
1243
.
17.
Moskowitz
CH
,
Nademanee
A
,
Masszi
T
, et al
;
AETHERA Study Group
.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
.
Lancet
.
2015
;
385
(
9980
):
1853
-
1862
.
18.
Chen
R
,
Zinzani
PL
,
Fanale
MA
, et al
;
KEYNOTE-087
.
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma
.
J Clin Oncol
.
2017
;
35
(
19
):
2125
-
2132
.
19.
Younes
A
,
Santoro
A
,
Shipp
M
, et al
.
Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
.
Lancet Oncol
.
2016
;
17
(
9
):
1283
-
1294
.
20.
Armand
P
,
Engert
A
,
Younes
A
, et al
.
Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial
.
J Clin Oncol
.
2018
;
36
(
14
):
1428
-
1439
.
21.
Connors
JM
,
Jurczak
W
,
Straus
DJ
, et al
;
ECHELON-1 Study Group
.
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma
.
N Engl J Med
.
2018
;
378
(
4
):
331
-
344
.
22.
Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price
:
2019
ASP drug pricing
. .
23.
Lakdawalla
DN
,
Doshi
JA
,
Garrison
LP
Jr
,
Phelps
CE
,
Basu
A
,
Danzon
PM
.
Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]
.
Value Health
.
2018
;
21
(
2
):
131
-
139
.
24.
Neumann
PJ
,
Sanders
GD
.
Cost-Effectiveness Analysis 2.0
.
N Engl J Med
.
2017
;
376
(
3
):
203
-
205
.
25.
Sanders
GD
,
Neumann
PJ
,
Basu
A
, et al
.
Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine
.
JAMA
.
2016
;
316
(
10
):
1093
-
1103
.
26.
Huntington
SF
,
von Keudell
G
,
Davidoff
AJ
,
Gross
CP
,
Prasad
SA
.
Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma
.
J Clin Oncol
.
2018
;
36
(
33
):
3307
-
3314
.
27.
Delea
TE
,
Sharma
A
,
Grossman
A
, et al
.
Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma
.
J Med Econ
.
2019
;
22
(
2
):
117
-
130
.
28.
Ramchandren
R
,
Advani
RH
,
Ansell
SM
, et al
.
Brentuximab vedotin plus chemotherapy in North American patients with newly diagnosed stage III or IV Hodgkin lymphoma
.
Clin Cancer Res
.
2019
;
25
(
6
):
1718
-
1726
.
29.
Evens
AM
,
Cilley
J
,
Ortiz
T
, et al
.
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
.
Br J Haematol
.
2007
;
137
(
6
):
545
-
552
.
30.
Aleman
BMP
,
van den Belt-Dusebout
AW
,
Klokman
WJ
,
Van’t Veer
MB
,
Bartelink
H
,
van Leeuwen
FE
.
Long-term cause-specific mortality of patients treated for Hodgkin’s disease
.
J Clin Oncol
.
2003
;
21
(
18
):
3431
-
3439
.
31.
Lane
JD
,
Friedberg
MW
,
Bennett
CL
.
Associations between industry sponsorship and results of cost-effectiveness analyses of drugs used in breast cancer treatment
.
JAMA Oncol
.
2016
;
2
(
2
):
274
-
276
.
32.
Hui
L
,
von Keudell
G
,
Wang
R
, et al
.
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation
.
Cancer
.
2017
;
123
(
19
):
3763
-
3771
.
33.
Moskowitz
CH
,
Walewski
J
,
Nademanee
A
, et al
.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
.
Blood
.
2018
;
132
(
25
):
2639
-
2642
.
34.
Engstrom
A
.
The cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma in Sweden [abstract]
.
Value Health
.
2014
;
17
(
7
):
A639
.
35.
Khachatryan
GR
,
Fedyaev
DV
,
Avxentyeva
MV
,
Dombrovskiy
VS
.
Cost-effectiveness analysis of brentuximab vedotin in adults with relapsed or refractory Hodgkin’s lymphoma [abstract]
.
Value Health
.
2016
;
19
(
7
):
A734
.
36.
National Institute for Health and Care Excellence
.
Final appraisal determination: brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
. .
37.
Towle
EL
,
Barr
TR
,
Senese
JL
.
The National Practice Benchmark for oncology, 2014 report on 2013 data
.
J Oncol Pract
.
2014
;
10
(
6
):
385
-
406
.
38.
Balogh
EP
,
Bach
PB
,
Eisenberg
PD
, et al
.
Practice-changing strategies to deliver affordable, high-quality cancer care: summary of an Institute of Medicine workshop
.
J Oncol Pract
.
2013
;
9
(
6 suppl
):
54s
-
59s
.
39.
American Society of Clinical Oncology
.
The state of cancer care in America, 2016: a report by the American Society of Clinical Oncology
.
J Oncol Pract
.
2016
;
12
(
4
):
339
-
383
.
40.
Alpert
A
,
Hsi
H
,
Jacobson
M
.
Evaluating the role of payment policy in driving vertical integration in the oncology market
.
Health Aff (Millwood)
.
2017
;
36
(
4
):
680
-
688
.
41.
McCaughan
M.
Health policy brief: the 340B drug discount program
.
Health Aff (Millwood)
.
14 September 2017; DOI 10.1377/hpb2017.10
.
42.
Desai
S
,
McWilliams
JM
.
Consequences of the 340B drug pricing program
.
N Engl J Med
.
2018
;
378
(
6
):
539
-
548
.
43.
Mitchell
AP
,
Rotter
JS
,
Patel
E
, et al
.
Association between reimbursement incentives and physician practice in oncology: a systematic review
.
JAMA Oncol
.
2019
;
5
(
6
):
893
-
899
.
44.
Abutalib
SA
,
Armitage
JO
.
ECHELON-1: a commendable study, but questions remain
. .
45.
National Cancer Institute, Surveillance, Epidemiology, and End Results Program
.
Cancer stat facts: Hodgkin lymphoma
. .
46.
Aitken
M
,
Kleinrock
M
,
Simorellis
A
,
Nass
D
.
Global oncology trends 2018: innovation, expansion and disruption. Durham, NC: IQVIA Institute for Human Data Science; 2018 May 24
. .
47.
Chen
Q
,
Jain
N
,
Ayer
T
, et al
.
Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States
.
J Clin Oncol
.
2017
;
35
(
2
):
166
-
174
.
48.
Bach
PB
.
Limits on Medicare’s ability to control rising spending on cancer drugs
.
N Engl J Med
.
2009
;
360
(
6
):
626
-
633
.
49.
Tay-Teo
K
,
Ilbawi
A
,
Hill
SR
.
Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies
.
JAMA Netw Open
.
2019
;
2
(
1
):
e186875
.
50.
Neumann
PJ
,
Cohen
JT
,
Weinstein
MC
.
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
.
N Engl J Med
.
2014
;
371
(
9
):
796
-
797
.
51.
US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation
.
Comparison of U.S. and international prices for top Medicare part B drugs by total expenditures
. .
52.
Hwang
T
,
Vokinger
K
,
Tibau
A
, et al
.
Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe [abstract]
.
Ann Oncol
.
2018
;
29
(
suppl 8
):
mdy424.078
.
53.
Cole
AL
,
Dusetzina
SB
.
Generic price competition for specialty drugs: too little, too late?
Health Aff (Millwood)
.
2018
;
37
(
5
):
738
-
742
.
54.
Atteberry
P
,
Bach
PB
,
Ohn
JA
,
Trusheim
M
.
Biologics are natural monopolies (part 1): why biosimilars do not create effective competition
.
15 April 2019
. .
You do not currently have access to this content.